Bordetella bronchiseptica is known to be endemic in many guineapig (Cavia porcellus) colonies, and periodically is the aetiological agent of fatal epizootics of bronchopneumonia. A commercial, non-adjuvant B. bronchiseptica bacterin, which is approved for use in canines, was evaluated for induction of a protective immune response in Strain 13/N guineapigs against an airborne challenge of virulent B. bronchispeptica in smallparticle aerosol. Seronegative animals were vaccinated on days 0 and 21 with intramuscular injections of O· 2 ml of bacterin. Humoral antibody titres of the vaccinated animals, as determined by ELISA, ranged from 128-1024 on day 49. On day 30 following the second dose of bacterin (study day 51), 12 vaccinated and 12 PBS sham-vaccinated animals were exposed to an inhaled dose of 4·3 X lOS CFU of B. bronchiseptica (325 LDso). Vaccinated, challenged animals remained clinically normal, although each guineapig did develop a localized upper respiratory infection. The rate of weight gain as well as rectal temperature of these animals were analogous to those exhibited by the control groups. Examination of 4 of the vaccinated, challenged animals on day 7 after exposure showed bacteria present in moderate to high numbers in the larynx and trachea but only minimally detectable in the lungs; by 30 days after exposure, the numbers of bacteria in the ·Present address: Virginia-Maryland Regional
larynx and trachea were diminshed, with none being detected in the lungs. Pathological alterations induced by B. bronchiseptica were not detected at either day 7 or day 30 after challenge in any of the vaccinated, challenged animals. Protection induced in Strain 13/N guineapigs by the commercial canine bacterin was sufficient to preclude the development of pulmonary disease, even in animals presented with a massive challenge of virulent bacteria in a small-particle aerosol.
Keywords: Bordetel/a bronchiseptica; Bacterin; Guineapig; Strain 13; Bronchopneumonia; Aerosols; Bordetel/osis; Cavia porcellus Enzootic pneumonia in the guineapig (Cavia porcel/us), first described in 1913, was shown to be caused by Bordetel/a bronchiseptica (Smith, 1913) . Fatal epizootics of this common respiratory pathogen continue to occur among guineapig breeding colonies (Ganaway et al., 1965; Woode & McLeod, 1967; Nikkels & Mullink, 1971 ). Further, the organism can induce abortion, still births, infertility, and otitis media in guineapigs (Ganaway, 1976; Wagner et al., 1976; Manning et al., 1984) . Daily prophylactic administration of antibiotics normally will prevent B. bronchiseptica outbreaks, but will not totally eliminate the bacteria; any lapse in drug therapy results in recrudescence of disease (Ganaway et al., 1965) . Because of the management problems and the absence of bactericidal action associated with daily antibiotic therapy, vaccination is the preferred preventive method for B. bronchiseptica outbreaks among guineapigs (Ganaway et al., 1965; Woode & McLeod, 1967; Nickkels & Mullink, 1971; Nakagawaetal., 1974; Shimizu, 1978) .
Periodic epizootics of acute, fatal B. bronchiseptica bronchopneumonia have occurred in the Strain 13/N guineapig conventional production colony at our Institute. Control of the infectious agent was accomplished by instituting a programme of routine vaccination of weanling guinea pigs with an autogenous bacterin, as previously recommended (Ganaway et al., 1965) . The bacterin used had been prepared by and was obtained from Comparative Pathology Section, Veterinary Resources Branch, National Institutes of Health (Bethesda, MD). Availability of the bacterin was terminated. Since preparation of an autogenous product is extremely laborious plus the desired degree of standardization often may be lacking, a suitable commercial vaccine was sought as a replacement.
Several commercial vaccines are available against Bordetella sp. and have been approved for use in dogs, humans, and pigs. The antigenic relatedness among isolates of B. bronchispetica obtained from different species strongly indicated that one of the commercial vaccines possibly could be used to induce protective immunity in guineapigs (Pedersen, 1975) . Most of the commercial products have aluminium hydroxide incorporated as an adjuvant, which has been shown to cause extreme local tissue reactions in guineapigs (Ganaway, personal communication). Thus, it was a prerequisite that the product selected for prophylaxis in guineapigs did not contain aluminium hydroxide. Of the vaccines available, one (Bronchicine, Dellen Labs, Inc, Omaha, NE) met the desired characteristics, plus it had been shown to induce protection in dogs against an airborne challenge of virulent B. bronchiseptica (Shade & Rapp, 1982) .
Previously, we reported that guineapigs exposed to small-particle aerosols of varying concentrations of virulent B. bronchiseptica developed a spectrum of disease that ranged from inapparent illness to fulminant bronchopneumonia (Trahan et al., 1987) . The purpose of this study was to
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evaluate the efficacy of a non-adjuvant vaccine (Bronchicine, Dellen Labs, Inc, Omaha, NE) to induce protective immunity in Strain 13/N guineapigs against a lethal challenge of virulent B. bronchiseptica, presented in a small-particle aerosol.
Materials and methods

Animals
Inbred Strain 13/N female guineapigs, 6 weeks old (390-450 g), were obtained from the Institute's conventional production colony. Selected animals did not exhibit humoral antibodies to B. bronchiseptica, as determined by 3 separate sera evaluations conducted 24, 14, and 3 days prior to the start of the vaccination regimen. Serum samples for antibody assay were extracted from 2 ml blood samples obtained from the anterior vena cava (Whorton, 1982) . Bleeding was accomplished after administration of 30 mglkg ketamine (Vetalar, Park Davis, Morris Plains, NJ) and 6 mglkg xylazine (Rompun, Haver-Lockhardt, Shawnee, KS). Each animal was ear-tagged for identification and individually housed in polycarbonate cages maintained within ventilated racks (Ventilated Animal Rack, Lab Products, Inc, Rochelle Park, NJ). Control animals were housed within the same room but in racks separate from exposed animals. Openformula guineapig ration (NIH Production Guinea Pig Chow, Agway, Inc, St. Mary's, OH) and water were provided ad libitum throughout the study.
Vaccination
Animals were vaccinated by giving 2 intramuscular injections of O· 2 ml of bacterin (Bronchicine, Dellen Labs, Inc, Omaha, NE) or phosphate buffered saline (PBS) on days 0 and 21. The bacterin is a cellular extract of antigenic material from a highly immunogenic strain of B. bronchiseptica that is recommended for prevention of canine bordetellosis, and as an aid in controlling infectious canine tracheobronchitis (Aronson, 1983) . Aluminium hydroxide is not a component of the bacterin.
Bacterium
A frozen ( -70°C) stock culture of a guineapig isolate of B. bronchiseptica, Strain SHGP-l, was revived, incubated, concentrated, and resuspended to a concentration of 1. 7 X 10 9 colony forming units (cfu/ml), as previously described (Trahan et al., 1987) .
Respiratory challenge
Animal exposure was performed with whole body dynamic aerosol equipment as described previously (Larson et al., 1980) . The Henderson-type aerosol transit tube was modified by incorporation of an animal-exposure box. Each animal was exposed for 10 min to a predetermined concentration of B. bronchiseptica. Respiratory minute volumes were estimated in accordance with Guyton's formula (Guyton, 1947) . Total inhaled doses were calculated using the minute volumes and the aerosol concentrations of bacteria delivered.
Bacterial assay
Colony assay and bacteria identification procedures were as described previously (Trahan et al., 1987) .
Serology
Serum for antibody determinations was obtained from blood withdrawn from each guineapig on days 24, 14, and 3 before commencement of the study. After vaccination, blood for serum was obtained from each animal on day 49 (28 days after the second vaccine dose), and on day 81 from each survivor. Humoral antibodies were quantitated using an enzyme-linked immunosorbent assay (ELISA) which was described previously (Trahan et al., 1987) .Titres, expressed as the reciprocal of serum dilution, were considered positive at a value of 32. This was a 2-fold dilution higher than the highest positive reaction due to non-specific binding of titrated antibody noted in blank control wells (i.e. wells without antigen).
Pathology
Tissues for histopathological examination, which 263 included all major organs and vaccination site musculature, were fixed in a solution of 10% formaldehyde in PBS (pH 7 '4), embedded in paraffin wax, sectioned at 6 JA.m, and stained with haematoxylin and eosin. Select tissue sections were stained by the Brown and Brenn procedure or the Brown and Hopps procedure (Luna, 1968) .
Experimental design
Seronegative guineapigs were randomly allocated to one of 5 groups (Table 1) . Animals in groups 1 and 3 each received O' 2 ml of undiluted bacterin on days 0 and 21; animals in group 4 were given a sham inoculation of PBS, the diluent for the bacterin; and animals in groups 2 and 5 were not injected with either bacterin or diluent. Seven days before the initial bacterin injection, daily determination of body weight and rectal temperature was begun and continued throughout the study. On day 51 (30 days after the second vaccine dose), animals in groups 3 and 4 were exposed to an inhaled dose of 4, 3 x lOS cfu of virulent B. bronchiseptica, which is equivalent to 325 median lethal doses (LDso). Groups 1 and 2 were exposed to an aerosol of sterile bacterial culture diluent (tryptose phosphate broth). The animals in group 5 represented unvaccinated, unchallenged controls. Each animal was visually evaluated twice daily after 
Results
Clinical observations
The rate of weight gain and rectal temperature of each guineapig in each group were maintained 100
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within the expected normal ranges prior to aerosol challenge (Figs 1 and 2). Analysis of variance among the groups showed that administration of vaccine or PBS did not exert any effect on these parameters (P<O·OOOI) . Exposure of animals in groups 1 and 2 to a smallparticle aerosol of sterile tryptose phosphate broth, the diluent, had no detectable effect on either the rate of weight gain, rectal temperature, or clinical status of individual animals, as compared to those animals in group 5 that did not receive an aerosol exposure. Since significant differences were not detected by analysis of variance among the control groups I, 2 and 5 for either weight gain (P<O'OOOl) or rectal temperature (P<O'OOOI), the data of these 3 groups were combined for illustrative purposes (Figs 1  and 2) . Animals that were given vaccine (group 3) remained clinically normal throughout the Weight gain of guineapigs either vaccinated with inactivated Bordetella bronchiseptica bacterin or sham-vaccinated with PBS and exposed to virulent bacteria, as contrasted with control groups of guineapigs. Vaccine or PBS (sham) injections were given on days 0 and 21. Guineapigs were exposed to an inhaled dose of 4,3 X 10 5 virulent B. bronchiseptica on day 51. Bars represent SEM. duration of the study (Table 1) ; the rate of weight gain and rectal temperatures of the vaccinated guineapigs remained analogous to those evidenced in the three control groups of animals (ANOV A P < 0·000 1). By contrast, a febrile response > 39,5°C was observed in all animals in group 4 (sham vaccine, virulent challenge) by day 3 after challenge (study day 54) and was sustained until death. Weight gain among animals in group 4 totally ceased by day 3 after challenge, with subsequent losses of 15-20070body weight. Four of the animals in group 4 were dead and the remaining 8 were moribund on day 6 after challenge; moribund animals were euthanized at that time (Table 1) .
Serology
Humoral antibody titres on day 49 in vaccinated animals (groups 1 and 3) ranged from 128 to 1024; neither unvaccinated nor sham-vaccinated animals exhibited demonstrable antibody titres (Table 1) . Titres on day 30 after challenge (study day 81) among the vaccinated animals that received the virulent challenge (group 3) increased 4 -to 6-fold, while titres remained constant among the vaccinated, unchallenged animals (group 1).
Pathology
Since 4 of the animals in group 4 were dead and the remaining were moribund on day 6 after challenge (study day 57), each of these animals was examined for the development of pathological alterations. Four animals from each of the other groups (groups 1, 2, 3 and 5) were killed on day 7 after challenge to determine corresponding pathological alterations that were present but not clinically evident. The surviving animals in groups 1, 2, 3 and 5 were killed on day 30 after challenge (study day 81). Gross pathological lesions were observed only in the sham-vaccinated, virulent challenge group of animals (group 4) and were identical to the lesions previously reported (Trahan et al., 1987) . Each animal exhibited congested conjunctivae, dried mucopurulent crusts in the medial and lateral canthi and occlusive crusts in the nares.
Transparent straw-coloured fluid of varying amounts was present in the thoracic cavity. White to blood-tinged frothy material consistently was detected in the trachea. There were numerous pulmonary lesions throughout the parenchyma of the middle and caudal lobes of the lungs of each animal. The lesions were irregularly shaped, well demarcated, reddishgrey, and varying in size from 5-20mm. No pathological alterations were observed in any other organ.
Histopathological changes observed among the animals of group 4 (sham vaccine, virulent challenge) were limited to necrotizing bronchopneumonia and necrotizing tracheitis, as previously described (Trahan et al., 1987) . The degree of severity of the alterations varied from moderate to severe and were attributable to B. bronchiseptica infection. The bacteria were present in large concentrations within the lung lesions, as demonstrated by the Brown and Brenn and the Brown and Hopps staining procedures.
Among the animals of groups 1, 2, 3 and 5 that were killed on day 7 and on day 30 after challenge, specific histopathological changes induced by B. bronchiseptica were not detected, although an occasional animal exhibited minimal alterations in the cellular architecture. Normal tissue histopathology was observed at the injection sites in each of the injected animals.
Bacteriology
A semi-quantitative method of analysis was employed as bacteriological and pathological evaluations were performed using the same animals. Guineapigs that were sham-vaccinated and given a virulent challenge (group 4) evidenced acute bronchopneumonia and yielded high numbers of B. bronchiseptica from the larynx, trachea and lungs when examined in the moribund state or immediately after death ( Table 2) . Examination of 4 of the vaccinated, challenged animals (group 3) on day 7 after receiving the aerosol exposure, the day after which the unvaccinated challenged animals had succumbed, showed that B. bronchiseptica were present in the larynx and trachea in moderate to high numbers but only minimally detectable in the lungs. At 30 days after exposure (study day 81), there was a diminution in the numbers of bacteria in the larynx and trachea of group 3 animals; B. bronchiseptica could not be detected in the lungs of these animals at this time. Positive identification of B. bronchiseptica was not made at either day 7 or day 30 after challenge in any of the remaining animals (groups 1, 2 and 5). The inability to detect B. bronchiseptica in either group 2 or group 5 animals provided further evidence of an absence of endemic infections among the guineapigs selected for the study.
Discussion
Although a microbial pathogen may be endemic within a given population, each animal within the population will not necessarily be infected, as indicated in this study by the continued presence of seronegative and culture negative control animals. The highly sensitive and specific ELISA procedure used accurately demonstrated previous exposure of animals to B. bronchiseptica, as contrasted to previous reports using the less sensitive microagglutination assay (Matherne et al., 1987) . Unidentified infected animals in a guineapig colony, typically as the result of insensitive seroassays, consequently serve as the source of virulent organisms for epizootics. Guineapig survivors of epizootics of B. bronchiseptica bronchopneumonia have minimal, if any, value for use in biomedical investigations. Thus, prevention of disease outbreaks in a conventional colony enhances the quality of the animal model available and, in turn, leads to enhanced accuracy and reproducibility of research results.
Control, if not elimination, of epizootics of B. bronchiseptica has been shown to be best accomplished through the judicious use of autogenous vaccine (Ganaway et al., 1965; Woode & McLeod, 1967; Nikkels & Mullink, 1971; Nakagawa et al., 1974; Shimizu, 1978) .
The use of autogenous vaccine, however, necessitates large expenditures of manhours for continued preparation of immunogen, while desired standardization often may be lacking.
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A significant humoral immune response was elicited to parenteral injection of the nonadjuvant, commercial vaccine (Bronchicine) by Strain l3/N guineapigs, which are exceptionally sensitive to fulminant infections by B. bronchiseptica. Protection provided by the immune response precluded the development of pulmonary disease, but did not prevent colonization of the larynx and trachea which was accompanied by a localized infection. The localized infection in the larynx and trachea, however, was not sufficient to induce detectable histopathological alterations.
Mucosal immunity is known to exert a primary effect in the development of infections that occur within, on, or via the respiratory and gastrointestinal mucosal epithelial cells (Bienenstock, 1984; Anderson et al., 1987) . The current hypothesis is that secretory IgA is important for protection of upper respiratory tract structures and IgG isotypes become more important deeper into the lungs. Inducement of either mucosal immune responses (lgA) or cell-mediated immunity was not measured in this study. It has been shown that inactivated immunogen preparations of Venezuelan equine encephalitis virus, Rift Valley fever virus, and Bacillus anthracis induce protective immune responses to parenteral administration of virulent organisms; yet, protective immune responses to airborne challenges of these organisms requires the use of a live, attenuated immunogen (Jahrling & Stephenon, 1984; Ivins et al., 1986; Anderson et al., 1987; Stephenson, unpublished data) . Possibly the adjuvant effect of the lipopOlysaccharide portion of B. bronchiseptica accentuates the immune response stimulated by the inactivated Bordetella vaccine, and is responsible for the degree of protection that was observed in the presence of the massive small-particle aerosol challenge. Secondly, elimination of the immense numbers of virulent bacteria that were deposited into the lungs may have been accomplished by the IgG isotypes induced by the bacterin, whereas an absence or minimal stimulation of secretory IgA production may correlate with the continued presence of challenge bacteria in the larynx and trachea. Also, the degree of protection induced may be directly related only to the relative number of virulent organisms in the inhaled dose; colonization and localized infection may not result in the presence of minimal numbers of infectious bacteria.
Our approach of using small-particle aerosol as the mode of challenge with virulent B. bronchiseptica simulates the natural exposure that occurs when animals are maintained in infected colonies. The whole-body aerosol exposure system yields a preponderance of aerosol particles that are less than l/Lm in diameter, such as occurs with respiratory dissemination. These particles readily penetrate the air passages to the alveoli, giving an even distribution throughout the respiratory system. By contrast, airborne transmission that employs administration of bacterial suspensions by intranasal instillation yields particles that are greater than 2/Lm in diameter, which results in deposition of the inoculum principally in the upper respiratory tract.
The continued presence of virulent B. bronchiseptica in the larynx and trachea of the vaccinated animals provides further evidence for previously infected animals being the reservoir of bacteria in a guineapig colony. If a non-vaccinated animal were to receive a minimal infectious inhaled dose of B. bronchiseptica, the animal would be expected to recover from the infection, develop a sufficient immune response to preclude disease upon further exposures, but remain a potential carrier. Carrier animals would then be the source of infectious bacteria to initiate epizootics when appropriate conditions arise.
Based on the data obtained from this study, a vaccination programme was implemented for the Strain 13/N guineapig colony in our Institute. Animals are given the 2-dose regimen, followed by a booster injection every 6 months. The 6-month booster injection interval was arbitrarily selected until definitive dose-response curves can be established. There has been no evidence of B. bronchiseptica-induced disease within the colony since the vaccination programme began. The quality of animals available for the Institute's research programmes has been improved. There has been an enhancement of investigations that use the Strain 13/N guineapigs in the absence of a respiratory challenge. When planning airborne disease studies, regardless of the challenge organism, consideration must be given to the potential of recrudenscence of bordetellosis among carrier animals in the presence of a compromise of the respiratory system. Preferably, animals selected for respiratory disease studies would be naIve, non-vaccinated animals, as used in this study. . 
